Kolon Life Science Incorporation operates within the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Kolon Life Science Incorporation with three other
companies in this sector in South Korea:
Hwail Pharmaceutical Company Limited
sales of 102.46 billion Korean Won [US$96.21 million]
CKD Bio Corp
(118.19 billion Korean Won [US$110.98 million]
Samil Pharmaceutical Co., Ltd.
(92.04 billion Korean Won [US$86.42 million]
During the year ended December of 2017, sales at
Kolon Life Science Incorporation were 118.10 billion Korean Won (US$110.90 million).
decrease of 25.4%
versus 2016, when the company's sales were 158.28 billion Korean Won.
Contributing to the drop in overall sales was the 97.0% decline
in Biotechnology Drugs, from 27.29 billion Korean Won to 824.00 million Korean Won.
There were also decreases in sales in
Environment Material (down 1.7% to 69.33 billion Korean Won)
Pharmaceutical Business (down 20.7% to 47.94 billion Korean Won)